NurExone Biologic is developing exosome-based therapies to regenerate nerves and recover function after Central Nervous System injuries.
Joined May 2021
- Tweets180
- Following486
- Followers408
- Likes86
globenewswire.com/news-relea…
An MOU with Nanopass will allow evaluation of clinically established MicronJet™ technology with our exosome formulations for optic nerve and skincare applications.
ExoPTEN for acute spinal cord injury continues to advance separately on its existing path.
🤖 Made with AI
We announced our Q1 2026 financial results and corporate update.
Read the full announcement: globenewswire.com/news-relea…
🤖 Made with AI
What if paralysis 👨🦽 wasn’t permanent - or at least not untreatable?
What if we could deliver regenerative signals to the central nervous system… through a simple intranasal spray?
In our latest @ProgressPotent1 episode, @liorshal (CEO of @NBiologic) breaks down the science behind ExoPTEN - an exosome-based therapy designed to deliver siRNA and temporarily silence the PTEN signaling pathway, one of the nervous system’s key “brakes” on regeneration. 🚀
In preclinical models, this approach has shown something rarely seen in this field: meaningful functional recovery after severe spinal cord injury.
We explore:
- Why the central nervous system struggles to regenerate;
- Whether exosomes can finally solve the delivery problem;
- Dr. Shaltiel’s journey - from ion channel biophysics to leading one of the more ambitious bets in neuroregeneration;
#Biotech #Neuroscience #SpinalCordInjury #RegenerativeMedicine #Exosomes #Neuroregeneration #GeneSilencing #FutureOfMedicine #HealthTech #Longevity
@russopartners @HebrewU
Join us at the Water Tower Research LLC Insights Conference, a virtual event for investors seeking direct access to innovative companies.
Register here: lnkd.in/eE59ij_4
NurExone’s session will take place on Tuesday, April 14, at 11:50 AM EST.
A really important milestone for NurExone....
Read more: globenewswire.com/news-relea…
Over the past year, the term "exosome" entered mainstream conversation, but much of the visibility came from cosmetic or plant-derived products. The next phase looks very different.
Do you agree that 2026 marks the shift to therapeutic reality for exosomes?
100%Yes
0%No
0%Too early to tell
8 votes • Final resultsWelcoming Eyal Gabbai to our Board!
He brings a strong mix of patient perspective, health-system economics and capital markets experience to help translate strong science into real-world care.
Read more: globenewswire.com/news-relea…
⚡ NurExone’s exosomes show significant anti-inflammatory activity, outperforming commercial alternatives in new laboratory analysis!
#Biotech #Exosomes #RegenerativeMedicine #Innovation #NurExone $NRX
Read here: lnkd.in/er_dyYRs
🗞️ Planning Small-Scale ExoPTEN Clinical Manufacturing in Preparation for Future First-in-Human Use Pathways!
#NurExone #ExoPTEN #Exosomes #Biomanufacturing #ClinicalReadiness
Read more: lnkd.in/dd9qjaCu
We released our Q3 results and corporate updates on Friday, highlighting scientific progress, strengthened IP, and continued momentum toward clinical readiness.
Read more: lnkd.in/du39EqS8
NurExone was nominated for The Galien Foundation Best Bridge Builder Award as we bridge academic research and applied innovation.
#SeeyouinStockholm #GalienPrix #BridgeBuilding
prnewswire.com/news-releases…
NurExone Biologic is pioneering a class of regenerative medicines that harness the body's own communication system to develop therapies with the potential to regenerate, repair & restore nerve function!
#Exosomes #ExoTherapy #BiotechInvesting #SpinalCord
The Jerusalem Post highlighted ScienceAbroad’s work connecting thousands of Israeli scientists worldwide, advancing collaboration, mentorship, and the global exchange of ideas.
Thank you Judy Siegel-Itzkovich for the wonderful coverage!
📖 Read here: jpost.com/science/article-87…
Read more about NurExone's Regenerative Therapy for CNS injuries under development: advancingrna.com/doc/develop…
clinicaltrialvanguard.com/ex…
Learn about NurExone and regenerative medicine in this great piece!
